

Indian Generic Drug Market Outlook 2020

<https://marketpublishers.com/r/I2CD5793BA8EN.html>

Date: August 2015

Pages: 90

Price: US\$ 800.00 (Single User License)

ID: I2CD5793BA8EN

Abstracts

Generics drugs are bioequivalent versions of the originator medicines. These drugs are cheaper and offer similar health benefits as those of branded counterparts. Generics are showing high penetration in the pharma market across the globe. In India, these drugs account for nearly 75% of the pharma market. This is due to the factors, such as rising healthcare expenditure, ageing population, high incidences of obesity, diabetes and cardiovascular diseases, as well as ongoing patent cliff of blockbuster drugs in the US and European markets. India is a market dominated by branded generics. Approximately 80% of the generics are off-patented drugs sold under brand names by big pharmaceutical companies like Pfizer, Bristol-Myer-Squibb and Glaxosmithkline among others. Branded generics are available at very high cost leading to affordability issues, particularly in rural india.

In the report “Indian Generic Drug Market Outlook 2020”, RNCOS analysts have endeavoured to address the current scenario of generics drug industry, factors favouring growth of the market, major roadblocks for the lack of penetration of unbranded drugs, and government initiatives to promote generic drugs. The report covers detailed description of the market size of generic drugs and its future forecast till 2020. Additionally, market segmentation of generic drugs by therapeutic segments is also included. RNCOS predicts that owing to the implementation of government schemes, like Jan Aushadhi, Free essential drug, and Sehat, the unbranded generic drug market is likely to show a promising growth in the near future. The generic drug market is anticipated to grow at a CAGR of 16.3% from 2014-2020.

The latter half of the report provides competitive landscape including the market shares of key players, such as Sun-Pharma, Dr. Reddys, Cipla, Lupin, Biocon, and others. Finally, a separate section comprising of opportunity assessment for the domestic generic manufactures is also added. The last part of the report describes several steps that need to be taken by the Government to promote unbranded drugs. On the whole,

the report provides information that will prove to be vital for investors interested in the domestic market.

Contents

1. ANALYST VIEW

2. RESEARCH METHODOLOGY

3. INDIA PHARMACEUTICAL MARKET OUTLOOK

4. DRIVERS

4.1 Rising Healthcare Expenditures

4.2 Increasing Disposable Incomes

4.3 Growing Ageing Population

4.4 Surging Lifestyle Diseases

4.4.1 Cardiovascular Diseases

4.4.2 Diabetes

4.4.3 Cancer

4.5 Ongoing Patent Cliff

5. CHALLENGES

5.1 Competition from Branded Drugs

5.2 Lack of Price-Control

5.3 Weak Supply Chain Management

5.4 Lack of Promotion

5.5 Quality Control

5.6 Lack of Awareness

6. SUPPLY CHAIN MODEL

7. REGULATORY LANDSCAPE

8. INDIA GENERIC OVERVIEW

8.1 Indian Market Performance Relative to the World

8.2 Market Size

8.3 Top Generic Drugs Globally

8.4 Major Generic Segments

9. CONSOLIDATIONS IN GENERICS INDUSTRY

10. GOVERNMENT INITIATIVES

10.1 Jan Aushadhi Scheme for the promotion of Generics Drugs

10.2 Free Essential Drug Scheme

10.3 Telemedicine Initiative “Sehat”

11. COMPETITION

11.1 Market Share of Major Players

11.2 Profiles

11.2.1 Sun Pharma

11.2.2 Cipla Limited

11.2.3 Biocon

11.2.4 Dr. Reddy's Laboratories

11.2.5 Lupin Ltd.

11.2.6 Aurobindo Pharma Limited

11.2.7 Wockhardt

11.2.8 Zydus Cadila

11.2.9 Glenmark

11.2.10 Jubilant LifeSciences

12. FUTURE OUTLOOK

13. GENERIC INDUSTRY: THE ROAD AHEAD

13.1 Opportunities

13.2 Recommendations

List Of Figures

LIST OF FIGURES:

Figure 3-1: Breakdown of India Pharmaceutical Market by Value (%) 2009-2014

Figure 3-2: Domestic Pharmaceutical Market (Billion US\$) 2014-2020

Figure 4-1: Healthcare Expenditure (% of GDP) 2009-2014

Figure 4-2: Personal Disposable Income (Billion US\$) 2009-2014

Figure 4-3: Population Above 65 Years (Million) 2009-2014

Figure 4-4: Diabetes Population (20-79 Years) Million 2013 & 2030

Figure 4-5: Number of Cancer Cases ('000) 2014 & 2020

Figure 6-1: Generic Supply Chain

Figure 7-1: Hierarchy of Ministry for Generic Drug Regulation

Figure 8-1: Share of India in Global Generics Market (%) 2014

Figure 8-2: India Generics Drug Market (Billion US\$) 2009-2014

Figure 8-3: Revenue Share of Major Generics Segments (%) 2014

Figure 11-1: Sun Pharma - Break up of Revenue by Therapeutic Segment (%), 2014

Figure 11-2: Sun Pharma - Break up of Revenue by Geography (%), 2014

Figure 11-3: Cipla Limited - Break up of Revenue by Geography (%), 2014

Figure 11-4: Biocon - Break up of Revenue by Geography (%), 2014

Figure 11-5: Dr. Reddy's Laboratories - Break up of Revenue by Geography (%), 2014

Figure 11-6: Lupin Limited - Revenues by Trade (Billion US\$), 2014

Figure 11-7: Aurobindo Pharma Limited - Break up of Formulations Revenue of by Geography (%), 2014

Figure 11-8: Wockhardt - Break up of Revenue by Geography (%), 2014

Figure 11-9: Zydus Cadila - Break up of Revenue by Geography (%), 2014

Figure 11-10: Glenmark - Break up of Revenue by Geography (%), 2014

Figure 11-11: Jubilant LifeSciences - Break up of Revenue by Geography (%), 2014

Figure 12-1: Generics Drug Market (Billion US\$) 2014-2020

List Of Tables

LIST OF TABLES:

Table 4-1: List of Blockbuster Drugs Losing Patent (2015-2020)

Table 8-1: Similarities and Differences Between Branded & Generics Drugs

Table 8-2: Top Generic Drugs Globally by Prescription (Million) 2014

Table 9-1: Major Consolidations in Indian Generic Industry (2014-2015)

Table 10-1: Comparative analysis of Jan Aushadhi Scheme (2008 & 2013)

Table 10-2: Pricing Details of Medicines under JAS Scheme

Table 10-3: Free Drugs Provided by States

Table 11-1: Market Share of Key Generics Players (%), 2014

Table 11-2: Sun Pharma - Revenues by Business Segment (Billion US\$), 2013 & 2014

Table 11-3: Biocon - Revenues by Business Segment (Billion US\$), 2013 & 2014

Table 11-4: Dr. Reddy's Laboratories - Revenues by Business Segment (Billion US\$), 2013 & 2014

Table 11-5: Lupin Limited - Revenues by Business Segment (Billion US\$), 2013 & 2014

Table 11-6: Aurobindo Pharma Limited - Revenues by Business Segment (Billion US\$), 2013 & 2014

Table 11-7: Zydus Cadila - Revenues by Business Segment (Billion US\$), 2013 & 2014

Table 11-8: Glenmark - Revenues by Business Segment (Billion US\$), 2013 & 2014

Table 11-9: Jubilant LifeSciences - Revenues by Business Segment (Billion US\$), 2013 & 2014

I would like to order

Product name: Indian Generic Drug Market Outlook 2020

Product link: <https://marketpublishers.com/r/l2CD5793BA8EN.html>

Price: US\$ 800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l2CD5793BA8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970